This study aimed to fill this gap by comparing the effectiveness of intravenous magnesium sulfate versus terbutaline in children with acute asthma exacerbations, providing evidence-based guidance for clinicians in emergency settings.
Despite the established roles of both magnesium sulfate and terbutaline in the management of severe asthma exacerbations, there is limited comparative data on their efficacy and safety in the pediatric population. Understanding the relative benefits and risks of these therapies is crucial for optimizing treatment strategies and improving patient outcomes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes
Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours
Nishtar Hospital
Multan, Punjab Province, Pakistan
Post-treatment PEFR
Post-treatment, children response to treatment was measured by noting PEFR
Time frame: 4 hours
Oxygen Saturation
Post-treatment, oxygen saturation was measured using Spirometry
Time frame: 4 hours
Heart Rate
Post-treatment, heart rate was measured
Time frame: 4-hours
Respiratory rate
Post-treatment, heart rate was measured.
Time frame: 4 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.